Episode 18: Matthew Likens, CEO, GT Medical Technologies
In this edition of the Tech Focus Member Spotlight, Matthew Likens, CEO at GT Medical Technologies, will talk about the breakthrough innovation, GammaTile Therapy, which allows patients to receive radiation treatment immediately starting at the time of surgery, and replaces the need for daily, on...
Episode Overview
In this edition of the Tech Focus Member Spotlight, Matthew Likens, CEO at GT Medical Technologies, will talk about the breakthrough innovation, GammaTile Therapy, which allows patients to receive radiation treatment immediately starting at the time of surgery, and replaces the need for daily, ongoing radiation treatments, while minimizing radiation side effects, including hair loss.
For decades, clinicians have sought better treatment options for patients with brain tumors that would effectively target tumor cells while preserving eloquent tissue. Driven to overcome the limitations of current treatments and raise the standard of care, a group of brain tumor specialists joined forces to address this critical, unmet need. Together with medical device experts, they developed GammaTile Therapy, Surgically Targeted Radiation Therapy (STaRT) for recurrent intracranial neoplasms. For more information visit: www.gtmedtech.com
